China Drug Approvals

top of page

Orpathys wins conditional NMPA approval for MET‑amplified gastric cancer in China | iPharmaCenter

Badari Andukuri

Jul 8

China Clears Vanflyta for FLT3-ITD Positive AML, Marking a New Option in Targeted Leukemia Care | iPharmaCenter

Badari Andukuri

Jun 19

Exdensur (depemokimab) wins NMPA approval in China for severe eosinophilic asthma

Exdensur (depemokimab) wins NMPA approval in China for severe eosinophilic asthma

Exdensur (depemokimab) wins NMPA approval in China for severe eosinophilic asthma

Badari Andukuri

Apr 4

China Approves Myqorzo and Redemplo, Expanding Options in Hypertrophic Cardiomyopathy and Familial Chylomicronaemia Syndrome | iPharmaCenter

ipharmaservices

Jan 23

China Grants Approval to Nucala for COPD Management | iPharmaCenter

ipharmaservices

Jan 7

Enhertu approved in China for HER2‑low or HER2‑ultralow metastatic breast cancer | iPharmaCenter

Badari Andukuri

Dec 31, 2025

China NMPA Approves Pfizer’s Matazisimab (You Ruiting) for Routine Prophylaxis in Hemophilia Patients with Inhibitors | iPharmaCenter

Badari Andukuri

Nov 28, 2025

Vyloytm (zolbetuximab) Gains Approval in China for First-Line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | iPharmaCenter

ipharmaservices

Jan 7, 2025

China Approves GSK’s Nucala for Chronic Rhinosinusitis with Nasal Polyps in Adults | iPharmaCenter

ipharmaservices

Jan 7, 2025

HUTCHMED and Innovent Announce Conditional Approval of Fruquintinib and Sintilimab Combination for Advanced Endometrial Cancer in China | iPharmaCenter

ipharmaservices

Dec 7, 2024

HUTCHMED Announces Continued Inclusion of Savolitinib in China’s National Reimbursement Drug List at Current Terms | China NRDL 2024 | iPharmaCenter

ipharmaservices

Dec 7, 2024

China's 2024 National Reimbursement Drug List Expands Access to 91 New Drugs | iPharmaCenter

China's 2024 National Reimbursement Drug List Expands Access to 91 New Drugs | iPharmaCenter

China's 2024 National Reimbursement Drug List Expands Access to 91 New Drugs | iPharmaCenter

ipharmaservices

Dec 7, 2024

AstraZeneca and Daiichi Sankyo’s drug, Enhertu approved in China for HER2-mutant mNSCLC | iPharmaCenter

ipharmaservices

Oct 14, 2024

China's NMPA Grants Approval for Padcev (Enfortumab Vedotin) for Advanced Urothelial Cancer | iPharmaCenter

ipharmaservices

Aug 24, 2024

Enhertu Receives Conditional Approval in China for Advanced HER2-Positive Gastric Cancer | iPharmaCenter

ipharmaservices

Aug 13, 2024

HUTCHMED's NDA for Tazemetostat in China Receives Priority Review for Relapsed/Refractory Follicular Lymphoma | iPharmaCenter

ipharmaservices

Jul 8, 2024

Leqembi Launched in China for Treating Alzheimer's Disease | 2024 | iPharmaCenter

Leqembi Launched in China for Treating Alzheimer's Disease | 2024 | iPharmaCenter

Leqembi Launched in China for Treating Alzheimer's Disease | 2024 | iPharmaCenter

ipharmaservices

Jul 2, 2024

China Approves Tagrisso Combined with Chemotherapy as First-Line Treatment for Advanced EGFR-Mutated Lung Cancer | 2024 | iPharmaCenter

China Approves Tagrisso Combined with Chemotherapy as First-Line Treatment for Advanced EGFR-Mutated Lung Cancer | 2024 | iPharmaCenter

China Approves Tagrisso Combined with Chemotherapy as First-Line Treatment for Advanced EGFR-Mutated Lung Cancer | 2024 | iPharmaCenter

ipharmaservices

Jun 26, 2024

China Drug Approvals | 2024 | iPharmaCenter

China Drug Approvals | 2024 | iPharmaCenter

China Drug Approvals | 2024 | iPharmaCenter

ipharmaservices

May 13, 2024

China Drug Approvals | 2023 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter

China Drug Approvals | 2023 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter

China Drug Approvals | 2023 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter

ipharmaservices

Dec 31, 2023

bottom of page